Vascular & Endovascular

The use of paclitaxel-coated balloons and stents in the femoropopliteal arteries of patients with peripheral artery disease (PAD) was associated with relative mortality increases of 68 percent and 93 percent at two and five years of follow-up, respectively, according to a meta-analysis published Dec. 6 in the Journal of the American Heart Association.

About 1 in 8 patients who received endovascular thrombectomy (EVT) for acute ischemic stroke during a two-year period in the U.S. were readmitted to the hospital within 30 days, according to an analysis of the Nationwide Readmissions Database published in JACC: Cardiovascular Interventions.

The FDA is amending its label for alemtuzumab, a drug used to treat multiple sclerosis (MS) and leukemia, after 13 patients reported cases of ischemic stroke, hemorrhagic stroke or arterial dissection related to use of the medication.

Medtronic has agreed to pay the U.S. Department of Justice (DOJ) a total of $50.9 million to settle three claims against Covidien and ev3, two companies Medtronic acquired in 2015.

High-risk transcatheter aortic valve replacement (TAVR) patients see the same rates of functional recovery and survival as surgical aortic valve replacement (SAVR) patients half a decade after their procedures, according to data published in the Journal of the American College of Cardiology.

Patients treated for carotid stenosis with a new mesh-covered stent demonstrated stroke rates of 1.1 percent at 30 days, suggesting the device could help overcome one of the previously reported weaknesses of carotid artery stenting.

An automated risk calculator derived solely from variables in an electronic health record (EHR) accurately predicted five-year survival in a community-based cohort of patients with peripheral artery disease (PAD), researchers reported Dec. 1 in the Journal of the American Heart Association.

The risk of major stroke was higher in the 30 days following surgical aortic valve replacement (SAVR) compared to transfemoral TAVR, according to a propensity-matched analysis from the PARTNER trials published Nov. 12 in the Journal of the American College of Cardiology.

Heart patients with symptoms of peripheral artery disease (PAD) continue to see low rates of prescriptions for antiplatelets, statins and ACE inhibitors, despite those drugs’ potential to prevent against major events like stroke, according to research published Nov. 15 in Stroke.

A decades-long study of patients who have migraines with visual aura has linked the painful headaches to an increased risk of experiencing atrial fibrillation and, to a lesser degree, stroke, researchers report in the online edition of Neurology.

Results of the CIRT trial presented at the American Heart Association Scientific Sessions dimmed hopes that low-dose methotrexate can reduce cardiovascular events but furthered researchers’ understanding of which inflammation-targeting therapies might succeed in that regard.

A machine learning algorithm that predicts five-year mortality among patients with atherosclerotic cardiovascular disease (ASCVD) makes the case that patient responses to questionnaires can be just as informative in risk stratification as clinical characteristics and lab measurements.